Dr Reddy's scrip gains nearly 4% on launching drug

Shares of Dr Reddy's Laboratories today rose by nearly 4 per cent after the company launched Somazina, a drug used for treating those who have suffered stroke, in India.
The stock ended at Rs 3,613.25, up 3.48 per cent on the BSE. During the day, it gained 3.67 per cent to Rs 3,620.
The scrip was the top gainer among the 30-Sensex stocks.
On the NSE, it rose by 3.6 per cent to settle at Rs 3,622.45.
The company's market valuation went up by Rs 2,046.93 crore to Rs 61,536.93 crore.
The Hyderabad-based firm has partnered with Spain's Ferrer Internacional SA to make Somazina available in India, Dr Reddy's Laboratories Ltd had said in a statement on Friday post market hours.

Somazina is used for the management of stroke and has been used for the treatment of post-stroke patients around the world.
It is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
In the broader market, the BSE index Sensex closed the day with a sharp gain of 363.30 points at 27,687.30.